Palo Alto, CA, United States
Palo Alto, CA, United States

Time filter

Source Type

News Article | November 21, 2016
Site: www.newsmaker.com.au

According to Stratistics MRC, the Global Personalized Medicine Market accounted for $94.49 billion in 2015 and is expected to reach $178.78 million by 2022 growing at a CAGR of 9.5% from 2015 to 2022.  Increased healthcare spending, growing incidence of cancer and rising adoption of next generation sequencing are few factors expected to fuel the market growth. Furthermore, government reimbursements for personalized medicine and regulatory scenario are the factors anticipated to propel the demand during the forecast period. However, complexity involved in usage of the drugs, huge development costs and inter-patient changeability of effects are some of the factors hindering the market. Access the complete report at: http://www.strategymrc.com/report/personalized-medicine-market North America commanded the market owing to technological advancements and increased R&D investments by various biotechnology companies in the region. However, the Asia-Pacific is expected to observe significant growth over the forecast period owing to the presence of a huge base of unmet market demand. Personalized medicines have major impact on SME’s and offer lucrative opportunities for these companies to expand their industrial boundaries across the world. Some of the key players in the market are Siemens Healthcare Diagnostics Inc., Sanofi, Quest Diagnostics, Qiagen Inc., Pfizer Inc., Laboratory Corporation of America, Illumina Inc., GE Healthcare, Foundation Medicine Inc., CardioDx Inc., Bristol-Myers Squibb, Becton Dickinson & Co., Asuragen Inc., Amgen Inc., Agendia NV, Abbott and 3G Biotech. Request for a sample at: http://www.strategymrc.com/report/personalized-medicine-market End Users Covered: • Academic Institutes and Research Laboratories • Bio and health informatics companies • Contract Research Organizations • Hospitals • Molecular Diagnostic Laboratories and Testing facilities • Other End Users o Venture capitalists o Service providers o Partners Regions Covered: • North America o US o Canada o Mexico • Europe o Germany o France o Italy o UK  o Spain      o Rest of Europe  • Asia Pacific o Japan        o China        o India        o Australia        o New Zealand       o Rest of Asia Pacific       • Rest of the World o Middle East o Brazil o Argentina o South Africa o Egypt What our report offers: - Market share assessments for the regional and country level segments - Market share analysis of the top industry players - Strategic recommendations for the new entrants - Market forecasts for a minimum of 7 years of all the mentioned segments, sub segments and the regional markets - Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations) - Strategic recommendations in key business segments based on the market estimations - Competitive landscaping mapping the key common trends - Company profiling with detailed strategies, financials, and recent developments - Supply chain trends mapping the latest technological advancements


Data Reinforce the Strong Evidence Base Supporting the Clinical Utility of the Corus® CAD Blood Test in Real-World Practice REDWOOD CITY, CA--(Marketwired - Nov 14, 2016) - CardioDx, Inc., a molecular diagnostics company specializing in cardiovascular genomics, announced results from the final endpoint analysis of the multi-center, community-based patient registry called the PRESET Registry (NCT01677156, A Registry to Evaluate Patterns of Care Associated with the Use of Corus CAD in Real World Clinical Care Settings). This analysis showed that the age, sex, and gene expression score (ASGES) derived from the Corus CAD blood test has clinical utility in the evaluation of outpatients presenting with stable symptoms suggestive of obstructive* coronary artery disease (CAD). Clinicians referred 10% of patients with low Corus CAD test scores (predefined as scores ≤ 15) versus 44% of patients with elevated scores (predefined as scores > 15) for further evaluation by cardiology or advanced cardiac testing (unadjusted Odds Ratio (OR) = 0.15, p < 0.0001; adjusted OR after accounting for clinical covariates = 0.18, p < 0.001.) Major adverse events and revascularization were noted in 3/252 (1.2%) patients with low Corus CAD scores and 14/314 (4.5%) patients with elevated Corus CAD scores (p < 0.03). The data was presented at the American Heart Association Scientific Sessions 2016, which took place on November 12-16 in New Orleans, La. The Corus CAD blood test integrates age, sex, and gene expression levels into a single score corresponding to the current likelihood of a blockage or significant narrowing in the coronary arteries. The test has previously shown clinical validity in the COMPASS study, in which the Corus CAD test outperformed myocardial perfusion imaging (MPI) as a diagnostic tool to exclude obstructive CAD by demonstrating a higher negative predictive value (96% vs. 88%, p < 0.001) than MPI for evaluating the presence of obstructive CAD.1 "The use of the age, sex, and gene expression score proved to be a valuable tool to identify a safe and effective course of care for those patients presenting with symptoms suggestive of obstructive CAD," said Joseph A. Ladapo, M.D., Ph.D., Assistant Professor of Medicine, Division of General Internal Medicine and Health Services Research, David Geffen School of Medicine at UCLA and lead author of the study. "Integrating the test into our approach for managing stable, symptomatic patients suspected of having obstructive CAD can help physicians provide effective and informative care for patients without exposing them to the risks of radiation or contrast dye associated with other, commonly used tests." The poster presentation, Primary Endpoint Results from a Community-Based Registry Evaluating the Use of a Blood-Based Age/Sex/Gene Expression Test in Patients Presenting with Symptoms Suggestive of Obstructive Coronary Artery Disease reported results from the PRESET Registry, which included 566 stable, non-acute and non-diabetic adult patients without a history of obstructive CAD from 21 primary care practices from September 2012 to August 2014. This final endpoint analysis evaluated both clinical decision-making and one-year safety follow-up among non-acute adult patients with typical or atypical symptoms suggestive of obstructive CAD. "Wider use of more effective approaches for the management of patients presenting with stable symptoms of coronary artery disease have been needed for some time," said Mark Monane, M.D., FACP, Chief Medical Officer of CardioDx. "The large number of community-based practices included in the PRESET Registry helped demonstrate the generalizability of Corus CAD in this setting. The final endpoint analysis with one-year follow-up post Corus CAD testing reinforces the fact that patients with low scores are unlikely to have major adverse cardiac events and revascularizations and thus helps to provide further confidence to clinicians for integrating Corus CAD into their primary care practices." About Obstructive Coronary Artery Disease Coronary artery disease (CAD) is a very common heart condition in the United States. One in seven deaths among Americans is caused by CAD.2 CAD can cause a narrowing or blockage of the coronary arteries (vessels to the heart that supply the heart with blood, oxygen, and nutrients), reducing blood flow to the heart muscle. This narrowing or blockage in the coronary arteries is often referred to as obstructive CAD, characterized by the presence of atherosclerosis, or plaque. About the Corus CAD Test Corus CAD is the first and only commercially available blood test that can safely and conveniently help primary care clinicians and cardiologists assess whether or not a stable non-diabetic patient's symptoms may be due to obstructive coronary artery disease. The test incorporates age, sex and gene expression measurements into a single score that indicates the likelihood of obstructive CAD. Clinicians use the Corus CAD score, along with other clinical information, to determine whether further cardiac testing is necessary, which can help patients avoid unnecessary exposure to radiation associated with medical imaging testing, as well as possible reactions to imaging dyes and/or potential complications from invasive cardiac tests requiring catheterization. The test involves a routine blood draw that is conveniently administered in the clinician's office. The Corus CAD test is the only sex-specific test for the evaluation of obstructive CAD because it accounts for cardiovascular differences between men and women. The test has been clinically validated in independent male and female patient cohorts, including two prospective, multicenter U.S. studies, PREDICT and COMPASS.3,1 In the COMPASS study, the Corus CAD test outperformed myocardial perfusion imaging (MPI) as a diagnostic tool to exclude obstructive CAD by demonstrating a higher negative predictive value (96% vs. 88%, p < 0.001) than MPI for assessing the presence of obstructive CAD.4 To date, over 200,000 Corus CAD test results have been provided to clinicians. CardioDx processes all Corus CAD test samples at its CLIA-certified and CAP-accredited clinical laboratory in Redwood City, California. The Corus CAD test has been recognized by The Wall Street Journal's Technology Innovation Awards, honored as a Gold Edison Award recipient, and named one of TIME's Top 10 Medical Breakthroughs. About CardioDx CardioDx, Inc., a molecular diagnostics company specializing in cardiovascular genomics is committed to developing clinically validated tests that empower clinicians to better tailor care to each individual patient. Strategically focused on coronary artery disease, CardioDx is committed to expanding patient access and improving healthcare quality and efficiency through the commercialization of genomic technologies. Please visit www.cardiodx.com for additional information. * Obstructive CAD is defined as at least one atherosclerotic plaque causing ≥50% luminal diameter stenosis in a major coronary artery ( ≥ 1.5 mm lumen diameter) as determined by invasive quantitative coronary angiography (QCA) or coronary computed tomography angiography (CTA) ( ≥ 2.0 mm). 1 Thomas GS, Voros S, McPherson JA, et al. A Blood-Based Gene Expression Test for Obstructive Coronary Artery Disease Tested in Symptomatic Nondiabetic Patients Referred for Myocardial Perfusion Imaging: The COMPASS Study. Circ Cardiovasc Genet. 2013;6(2):154-162. 2 Mozaffarian D, Benjamin EJ, Go AS, et al. On Behalf of the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart Disease and Stroke Statistics - 2016 Update: A Report from the American Heart Association. Circulation. 2016;133(4):e38-e360. 3 Rosenberg S, Elashoff MR, Beineke P, et al. Multicenter Validation of the Diagnostic Accuracy of a Blood-Based Gene Expression Test for Assessing Obstructive Coronary Artery Disease in Nondiabetic Patients. Ann Intern Med. 2010;153:425-434. 4 The COMPASS study demonstrated that the Corus CAD algorithm has an NPV of 96% at the pre-specified threshold of 15 in a population of men and women referred to MPI.


Research and Markets (http://www.researchandmarkets.com/research/5xjpnr/molecular) has announced the addition of the "Molecular Diagnostics Global Market Size, Strategies and Forecasts 2015 to 2019" report to their offering. A market that just keeps on growing. Molecular Diagnostics is positioned to directly benefit from the explosion in biotechnology, especially genomics. Learn all about it in this new report. A range of dynamic trends are pushing market growth and company valuations. The report data is designed to be used! The unit volumes of tests performed is presented. Use our pricing scenarios or use your own. Project your market share and your price to reliably generate revenue forecasts or understand your own current market share position. Detailed Market Forecasts provide Price, Volume and Revenue Forecasts individually broken out by year for Infectious Disease, Genetic Testing, Oncology Testing. Exciting technical developments especially in the area of pharmacogenics hold the promise of a dynamic, growing and evolving world market that is moving out of the national and regional orientation and onto a global stage. Report Buyers have access to Price and Volume Data for the following individual tests:


Patent
CardioDx | Date: 2012-08-24

Peripheral blood markers are provided whose expression levels correlate with smoking status. Predictive models developed using highly informative markers are disclosed, along with systems, kits, and methods for using the markers to provide a biochemical surrogate for a subjects smoking status. In some embodiments, the smoking-related disease is chronic obstructive pulmonary disease, chronic bronchitis, emphysema, lung cancer, and/or asthma.


Patent
CardioDx | Date: 2014-01-16

Markers and methods useful for assessing coronary artery disease in a subject are provided, along with kits for measuring their expression. Also provided are predictive models, based on the markers, as well as computer systems, and software embodiments of the models for scoring and optionally classifying samples.


Patent
CardioDx | Date: 2011-03-18

Disclosed herein is a method of do terming the likelihood of a sudden cardiac event, such as an arrythmia, in a subject. Also disclosed is a method of determining whether a subject is at risk of a sudden cardiac event arid whether the subject would benefit from a treatment such as implantation of an ICD.


Patent
CardioDx | Date: 2010-06-15

Markers and methods useful for assessing coronary artery disease in a subject are provided, along with kits for measuring their expression. Also provided are predictive models, based on the markers, as well as computer systems, and software embodiments of the models for scoring and optionally classifying samples.


Patent
CardioDx | Date: 2015-07-17

Markers and methods useful for assessing coronary artery disease in a subject are provided, along with kits for measuring their expression. Also provided are predictive models, based on the markers, as well as computer systems, and software embodiments of the models for scoring and optionally classifying samples.


Patent
CardioDx | Date: 2010-04-14

Biomarkers useful for diagnosing and assessing physiological age are provided, along with kits for measuring their expression. The invention also provides predictive models, based on the biomarkers, as well as computer systems, and software embodiments of the models for scoring and optionally classifying samples. In a preferred embodiment, the biomarkers include a group of biomarkers whose expression levels are highly correlated to each other. In a preferred embodiment, expression levels of CD248; CD248 and SLC 1A7; CD248 and one, two, three or four of the group consisting of CCR7, B3GAT1, VSIG4 and LR-RN3; or CD248, SLC1A7 and one, two, three or four of the group consisting of CCR7, B3GAT1, VSIG4 and LRRN3 are determined.


Grant
Agency: Department of Health and Human Services | Branch: | Program: SBIR | Phase: Phase I | Award Amount: 205.80K | Year: 2014

DESCRIPTION (provided by applicant): Current tube-based methods for collecting whole blood RNA such as PAXgeneTM have a number of limitations including need for access to phlebotomy, temperature controlled transport, and relatively large volumes of whole blood. No solid-matrix based methods for obtaining RNA from whole blood currently exist. Our goal is the development and implementation of a solid, matrix-based approach for obtaining and stabilizing both RNA and DNA from whole blood, which would address these limitations. In conjunction with investigators at General Electric, we have prototyped an initial platform, term RNA Stabilization Matrix (RSM). In the current proposal we plan to expand upon our initial work in four areas: (1) We plan to develop automated methods using liquid handling robotics for extracting RNA from RSM; such methods will increase throughput as well as decrease variability associated with manual processing. (2) We plan to develop methods allowing for whole transcriptome analysi

Loading CardioDx collaborators
Loading CardioDx collaborators